UNSPSC 51422408: Deflazacort

This classification denotes a therapeutic glucocorticoid with the molecular formula C25H31NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KR5YZ6AE4B, chemically known as 11beta,21-dihydroxy-2-methyl-5betah-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione 21-acetate but generally known as deflazacort, which bears US NIH Compound Identifier 26709. European Medicines Agency schedules Deflazacort in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06943MIG.

UNSPSC 51422408 Deflazacort is a Commodity code nominally identifying a single corticosteroid pharmaceutical product, but the recent state and local opportunities tagged under this code do not reflect pharmaceutical procurement aligned with deflazacort itself. Instead, the two most recent solicitations show activity in emergency-response pharmaceuticals and pharmacy benefit program innovation. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs for state pharmacy benefit administration, focusing on vendor capacity to contract directly with self-insured health plans and negotiate value-based pricing models outside traditional pharmacy benefit manager and group purchasing organization arrangements. The code shows little recent purchasing activity aligned with deflazacort specifically; the opportunities appear to reflect either misclassification or use of this code as a catch-all for pharmaceutical procurement that does not map cleanly to its nominal scope.

The geographic spread is limited to Florida and Texas based on the recent record. Issuing bodies include a county health department and a state health and human services commission. The Seminole County naloxone solicitation is an IFB with a response deadline of July 26, 2026, requiring electronic bid submission through the county's e-procurement portal, with contract terms including a two-year initial period plus a one-year renewal option, quarterly deliveries, E-Verify compliance, and standard insurance requirements. The Texas HHS RFI, posted April 3, 2026, functions as an exploratory information-gathering mechanism rather than a binding competitive procurement, designed to inform the state's strategy before issuing a formal RFP. Neither opportunity specifies set-aside or disadvantaged-enterprise designations. Code activity under this Commodity is sparse and misaligned with deflazacort purchasing; business development professionals should verify whether their deflazacort product or service actually maps to this code or whether state and local demand sits under a different UNSPSC classification.